GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Marizyme MRZM · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$645,810

FY2015FY2024

Net income

−$69.5m

FY2015FY2024

Free cash flow

−$4.7m

FY2015FY2024

Shareholders' equity

−$6.7m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$645,810$645,810$233,485$210,279$197,136—$20,187$101,175$291,135$407,708
Research and development$2.2m$2.2m$4.0m$1.7m$687,734—————
Operating income−$34.1m−$34.1m−$13.0m−$8.8m−$5.8m−$1.1m−$247,129−$124,912−$181,818−$1.2m
Net income−$69.5m−$69.5m−$38.2m−$11.0m−$5.8m−$1.1m−$248,743−$570,506−$872,712−$9.0m
Diluted earnings per share-1.53-0.53-0.94-0.30-0.16-0.05-0.06-0.04-0.77-0.20

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$22.0m$22.0m$38.7m$66.0m$47.1m$28.6m$28.6m$2.8m$3.0m$7.9m
Cash and short-term investments$148,465$148,465$510,865$4.1m$2.9m$90$104$51,608$11,883$14,369
Total liabilities$28.7m$28.7m$21.3m$18.3m$1.8m$270,218$42,780$652,670$291,105$4.3m
Debt$20.8m$20.8m$5.4m$1.8m$1.3m——−$2,396$87,216$1.1m
Shareholders' equity−$6.7m−$4.7m$17.4m$47.7m$45.3m$28.3m$28.6m$2.2m$2.8m$3.6m
Shares outstanding45m132m41m36m36m20m4m15m1m45m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$4.7m−$4.7m−$10.9m−$5.8m−$3.2m−$112,014−$218,903$39,725$160,511−$156,632
Capital spending−$2———−$148,656−$13,000————
Free cash flow−$4.7m−$4.7m−$10.9m−$5.8m−$3.4m−$125,014−$218,903$39,725$160,511−$156,632

Latest quarters

By quarter end

Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
Revenue———$32,855$150,562$181,535$184,739$128,974
Operating income−$1.4m−$1.4m−$1.6m−$1.4m−$8.0m−$4.9m−$4.8m−$2.1m
Net income−$2.0m−$2.0m−$4.1m−$6.2m−$9.8m−$32.5m−$20.6m−$2.6m
Diluted earnings per share-0.04-0.04-0.09-0.14-0.07-0.25-0.16-0.02
Cash from operations————−$1.0m−$1.0m−$1.0m−$1.0m
Total assets$21.3m$21.3m$21.5m$21.6m$22.0m$36.9m$37.0m$38.3m
Cash and short-term investments$63,732—$5,222$6,146—$474,944$205,226$329,805
Debt$26.3m—$20.0m$23.0m—$20.8m$13.5m$6.9m
Shareholders' equity−$15.5m−$15.5m−$9.4m−$10.8m−$6.7m−$21.9m$7.3m$15.2m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue45.4%——
Operating income56.9%100.3%39.4%
Net income84.9%131.0%21.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-5278.1%-5184.3%——
Net margin-10767.8%-10847.3%——

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020
Price to earnings———-0.0-0.0
Price to sales0.30.20.20.50.7

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-95%744%-50%-41%-39%4347%12958%1210%40%-32%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 29-to-1 reverse split · 27 Jul 2018

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.